VRTX Gap Fill Play - Bullish
- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis.
- Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts
- Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact.
- Price entering the gap from that day's drop.
- Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued.
- Bull flagging right under the gap.
Key Level: $232.41
Price Target: 269.93
ATR: $6.60
Play:
Bullish Gap Fill
Buy the Dip under the key level to scale in
Use $232.41 as inflection point.
Look for breakout with increased volume
Price Target: 270
Under $224 will invalidate
- Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts
- Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact.
- Price entering the gap from that day's drop.
- Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued.
- Bull flagging right under the gap.
Key Level: $232.41
Price Target: 269.93
ATR: $6.60
Play:
Bullish Gap Fill
Buy the Dip under the key level to scale in
Use $232.41 as inflection point.
Look for breakout with increased volume
Price Target: 270
Under $224 will invalidate
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.